4) PBA Medical Countermeasures
Abstract
Focuses on therapeutic and prophylactic strategies to effectively minimize injuries and/or death resulting from exposure to Pharmaceutical Based Agents (PBA). This will allow the Warfighter to maintain operational capacity in a chemically contested battlefield scenario. This effort involves the evaluation FDA approved therapeutics for operational use, as well as generation of novel drug products and formulations to enhance level of protection and/or operational utility for the Warfighter. Efforts in this area are designed to develop drug candidates that will ultimately be submitted for Food and Drug Administration (FDA) licensure or to identify previously licensed products for new uses in the treatment and pretreatment against chemical warfare injury.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- 1c045e582b1036ff9414966a308c4251